Corporate Presentation August 2016

ASH 2015 Investor and Analyst Event

ASH 2014 Investor and Analyst Event


2015 Annual Report
Download here


Derivative Lawsuit Settlement Information
Download here

Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Recent NewsMore >>
09/12/16Geron Provides Update on Imetelstat Trials Being Conducted by JanssenPrinter Friendly Version
09/11/16Geron Announces Conference Call on September 12 at 8:00 A.M. Eastern TimePrinter Friendly Version
08/03/16Geron Corporation Reports Second Quarter 2016 Financial Results and Recent EventsPrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 0.01 (0.48%)
Data as of 10/20/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Contact Information

Anna Krassowska, Ph.D.
Tel: 650-473-7700
E-mail: or

RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Form content here please :)